XTL BIOPHARMACEUTICALS LTD

XTL Biopharmaceuticals is an Israeli biopharmaceutical company focused on developing pharmaceutical treatments for autoimmune diseases. The company's primary asset is hCDR1, a drug candidate in Phase II development targeting systemic lupus erythematosus and Sjogren's syndrome. XTL operates under a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization rights to hCDR1 across multiple indications.

The company was incorporated in Israel in 1993 and rebranded from Xenograft Technologies Ltd. to XTL Biopharmaceuticals Ltd. in July 1995. Headquartered in Ramat Gan, Israel, the company operates with a small team of approximately 10 full-time employees. As a development-stage biopharmaceutical entity, XTL's business model centers on advancing its lead candidate through clinical trials rather than generating near-term revenue streams. The company is publicly listed on Nasdaq.